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In many patients the optimal method of investigation of peripheral pulmonary lesions (PPL) is
not clear. We performed a prospective randomized pragmatic trial to determine the compar-
ative effectiveness of endobronchial ultrasound-guided transbronchial lung biopsy (EBUS-
TBLB) and CT-guided percutaneous needle biopsy (CT-PNB) for the investigation of PPL. Overall
complication rates were higher in those undergoing CT-PNB (27% v 3%, p Z 0.03), while diag-
nostic accuracy of EBUS-TBLB was shown to be non-inferior to that of CT-PNB.
Expected diagnostic accuracy and complication rates are likely to differ for individual
patients on the basis of specific complex clinicoradiologic factors, which will influence the
cost-benefit analysis between EBUS-TBLB and CT-PNB for individual patients. Further studies
are required to examine the effect of these factors on clinical decision-making.
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Peripheral pulmonary lesions (PPL) are focal radiographic
opacities that may be characterized as nodules (3 cm) or
masses (>3 cm). While referral for lobectomy in patients
with a PPL with a very high pre-test probability oflsevier Ltd. All rights reserved.
EBUS v CT biopsy for PPL 1705malignancy is suggested by some guidelines,1 resectional
biopsy is not risk-free and may not be necessary in
a significant number of patients with such lesions.2 CT
screening studies show that up to 34% of such operations
are performed for benign nodules.3e5
Non-invasive tests such as FDG-PET or dynamic Comput-
erized Tomography (CT) with nodule enhancement cannot
distinguish benign from malignant disease with sufficient
accuracy.2 Consequently, attempts at minimally invasive
diagnosis are strongly favored. The two modalities most
commonly used to investigate PPLs are CT-guided percuta-
neous needle biopsy/aspiration (CT-PNB) or bronchoscopy.
Bronchoscopy may be limited by poor diagnostic yield,6,7
though sensitivity is improved by guidance techniques such
as fluoroscopy,7,8 virtual bronchoscopy,9 endobronchial
ultrasound (EBUS),8 or electromagnetic navigation (EMN).10
Clinical acumen may determine the choice of initial
investigation in many patients with PPL. For example, those
with radiographic evidence of probable mediastinal or
extra-thoracic metastases are best served by sampling the
metastatic disease site.11 Conversely, PPL with endobron-
chial involvement are best evaluated via bronchoscopy.11,12
Alternatively, expert review of imaging in patients referred
for evaluation of PPL may demonstrate that invasive biopsy
is not warranted, while in other patients, severe comorbid
disease renders tissue diagnosis unnecessary.
However, in a proportion of patients who require tissue
diagnosis, the optimal investigation remains unclear. This
may be influenced by diagnostic accuracy, complication
rates, and costs of individual procedures. Although the
individual diagnostic characteristics of both EBUS-guided
TBLB (EBUS-TBLB) and CT-PNB are well described, no study
has previously directly compared the two tests.
Comparative effectiveness research (CER) was recently
defined by the Institute of Medicine as “the generation and
synthesis of evidence that compares the benefits and harms
of alternative methods to diagnose, treat or monitor
a clinical condition”.13 We performed a randomized trial of
EBUS-TBLB versus CT-PNB for the investigation of solitary
PPLs, in patients who had no clinical features to mandate or
exclude either procedure. We compared the benefits
(diagnostic accuracy) and harms (complications) of the two
methods in order to guide clinicians in selection of the
optimal investigation.
Methods
Institutional review board approval was granted for the
performance of this study. All patients provided informed
written consent.
Trial design
This study was a prospective randomized pragmatic trial.
The continuum between pragmatic and explanatory trials
has been previously elucidated, with pragmatic trials noted
to be primarily designed to determine the effects of an
intervention under the usual conditions in which it will be
applied.14 Given our intention to provide evidence to guide
clinicians in selection the optimal investigation of patients
with PPLs, the trial was designed according to the PRECIStool in order to simulate “usual-care” conditions.14 Such
trial designs are well aligned with the purpose of CER.15 We
have adhered to the CONSORT guidelines for optimal
reporting of randomized trials of non-pharmacologic
treatment,16,17 and the STARD guidelines for reporting
studies of diagnostic accuracy.18
We hypothesized that the diagnostic accuracy of EBUS-
TBLB was non-inferior to that of CT-PNB, but that the
complication rate of EBUS-TBLB would be significantly
lower than CT-PNB. Non-inferiority was defined a priori as
diagnostic accuracy differing by not greater than 10%.
Primary study outcomes were procedural complication
rates and diagnostic accuracy.
Participants
All consecutive patients referred to our multidisciplinary
lung cancer service for initial evaluation of solitary PPL,
suspicious for lung cancer, were considered for inclusion in
the study. The multidisciplinary service is based at Royal
Melbourne Hospital, a tertiary referral centre and univer-
sity teaching hospital. All patients were reviewed in
a multidisciplinary meeting (MDM) to ensure that consensus
opinion is that investigation is warranted and that either
CT-PNB or EBUS would be acceptable modes of initial
investigation of the lesion. Clinicians could exclude
patients from the study if clinical acumen (on the basis of
clinicoradiologic features) suggested a higher diagnostic
accuracy or lower complications rate for one of the two
procedures, thus making the alternate procedure unac-
ceptable. The following exclusion criteria were applied
only to exclude those with PPLs not requiring investigation:
- clinical condition precludes investigation
- lesion <1 cm diameter anywhere in lung fields
- Evidence on CT scan of central (endobronchially visible)
lesion
- Other clinical site of disease more amenable to tissue
diagnosis
- Tissue diagnosis considered unnecessary by MDM
Randomization to either procedure was performed using
a computer-based random sequence generator (www.
randomization.com). Both subjects and clinicians were
unblinded to the randomization outcome. Subsequent
investigation in the event of a non-diagnostic procedure
was determined by the primary clinician.
Recorded data included patient demographics (age,
gender), clinicoradiologic information (lesion size, lobar
position, lesion distance from hilum and pleural, final
diagnosis) and procedural information (date, diagnostic (Y/
N), complications). All data was recorded prior to perfor-
mance of the diagnostic test.
Performance of EBUS-TBLB
Bronchoscopy with EBUS guidance was an established
technique at our institution for the investigation of
peripheral pulmonary lesions,19e21 with approximately 150
procedures completed in the 12 months prior to
commencement of the trial. Procedures were performed
1706 D.P. Steinfort et al.with topical lignocaine 2% and intravenous sedation, as
previously described.20 All procedures were performed by
a single physician (DPS) using a standard video-
bronchoscope (BF-P160, Olympus, Tokyo, Japan), with a 20-
MHz radial EBUS probe (UM-BS20e26R; Olympus, Tokyo,
Japan) and guide sheath.
Visible bronchial segments were sequentially examined
until the characteristic ultrasound signal indicating pres-
ence of solid lesions was demonstrated. The EBUS probe
was then removed and sampling instruments (biopsy
forceps, cytology brush) introduced through the guide
sheath, with sampling performed under fluoroscopic vision.
Bronchial washings were taken after performance of TBLB
and bronchial brushings. In the event that a PPL was not
located, only bronchial washings were performed.Performance of CT-PNB
Computed tomography-guided percutaneous needle biopsy
of lung lesions was performed using CT fluoroscopy using
a 64 detector CT scanner (Siemens Sensation 64, Siemens
Healthcare. Erlangen, Germany). Twelve biopsies were
performed by consultant radiologists (JMV, SH) and four
were performed by radiology registrars/fellows.
The lung lesion was localized by a limited CT scan through
the chest. Lignocaine 1% was injected into the skin and soft
tissues to the pleural surface. A coaxial needle (Bard Tru-
Guide needle, Bard Biopsy Systems. Tempe, AZ, USA) was
introduced to the periphery of the PPL and multiple core
biopsies (Bard Biopy-Cut needle and Bard Magnum biopsy
instrument. Bard Biopsy Systems. Tempe, AZ, USA) were
obtained. In fourteen of the fifteen biopsies a 19 g coaxial
needle and 20 g core needle were used. In one patient a 17 g
coaxial needle and 18 g core needle were used.
Following each diagnostic procedure, all patients
underwent routine CXR. CT screening of patients following
PNB was not performed, and diagnosis of pneumothorax
was only made by CXR. Final diagnoses in patients in whom
procedures were non-diagnostic were determined either on
the basis of a subsequent invasive biopsy procedure, or
were presumed benign on the basis of either regression of
the PPL during radiologic surveillance, or stability during
surveillance of a minimum 12 months duration.Figure 1 Flow diagram illustrating progression of all patients
referred for evaluation of PPL to our multidisciplinary service
during the study period.Statistical analysis
Continuous variables are expressed as mean  standard
deviation, with comparison performed using an unpaired t-
test (Welch-corrected). The ManneWhitney test was used
to compare non-parametric values. Categorical variables
are presented as simple proportions and compared using
Fisher’s exact test. All reported confidence intervals are
two-sided. Sensitivity, specificity, and accuracy of the two
methods were calculated according to standard definitions,
with comparison performed using Fisher’s exact test.
Comparison between groups was performed on an as-
treated basis. A p-value of less than 0.05 was considered
significant. Analyses were performed using GraphPad InStat
3 for Macintosh (GraphPad Software, La Jolla, CA. USA).Results
From February 7th 2008 until January 22nd 2010, 358
patients were referred to our multidisciplinary lung cancer
service for initial evaluation of a PPL. A flowchart illus-
trating the progression of consecutive unselected patients
referred for evaluation of PPL is presented in Fig. 1. At least
one exclusion criteria was met by 259 (72%) patients (see
Fig. 1).
Clinical acumen resulted in exclusion of 28 patients from
the trial. Two patients were preferentially referred for CT-
PNB as they had pleurally based PPLs felt to be more
amenable to percutaneous sampling. Twenty-six patients
were referred preferentially for EBUS-TBLB. Two of these
patients were refused by interventional radiologists con-
cerned at the risk of complications from CT-PNB (see
Fig. 2). The remaining 24 patients were declined by their
primary clinician; 23 due to concern regarding the risk of
pneumothorax complicating CT-PNB in patients with severe
COPD or bleeding complicating CT-PNB in patients on
anticoagulation, and one on the basis of an expected
diagnostic result for EBUS-TBLB in a patient with a peri-
hilar pulmonary nodule with a bronchus sign.
Eleven patients also declined to undergo randomization
to either procedure. Ten declined CT-PNB due to the risk of
Figure 2 Clinicians were able to exclude patients from
randomization if they felt there was an unduly high risk of
complications associated with one procedure. Two patients
were declined from CT-PNB by interventional radiologists on the
basis of a high risk of complications suggested by radiologic
appearances. A) CT chest demonstrates a left upper lobe nodule
adjacent to an emphysematous bullus, suggesting a high risk of
pneumothorax. B) CT/PET demonstrates FDG-avid lesion within
the left upper lobe abutting the aortic arch, raising concern
regarding of vascular trauma complicating the procedure.
EBUS v CT biopsy for PPL 1707pneumothorax, and one patient declined EBUS as CT-PNB
could be performed with shorter delay. Three patients were
not able to provide consent for inclusion in the trial.
Of the remaining 71 patients, 51 (72%) were randomized.
Demographic and clinicoradiologic data for the 51
randomized patients is recorded in Table 1.Diagnostic performance
Final diagnoses in all patients undergoing EBUS-TBLB or CT-
PNB are recorded in Table 2. Three patients randomized to
CT-PNB did not undergo biopsy: in one, the lesion had
resolved by the time of biopsy, a second patient subse-
quently declined invasive biopsy, and a third patient was
referred directly to surgery without biopsy after randomi-
zation. Outcome data for all subjects is recorded in Table 3.
Diagnostic accuracy was similar for both EBUS-TBLB and CT-
PNB (87.5% v. 93.3% respectively, p Z 1.0). The 95%
confidence interval for diagnostic accuracy of EBUS-TBLB iswithin the confidence interval for CT-PNB, therefore our
results indicate that EBUS-TBLB is non-inferior to CT-PNB
for the diagnosis of PPLs.22
No clinical factors were noted to influence the diag-
nostic performance of CT-PNB. For subjects undergoing
EBUS-TBLB, multiple factors were associated with improved
diagnostic sensitivity (Table 4). Diagnostic sensitivity was
significantly higher in patients in whom the PPL was located
by the probe (22 of 22 v. 5 of 10, p Z 0.001). Ability to
locate the PPL with the radial EBUS probe was significantly
associated with a diagnosis of primary lung cancer (19 of 28
patients with lung cancer v. 0 of 4 patients with non-lung
cancer diagnoses, p Z 0.020). EBUS was significantly
more likely to be diagnostic in patients with lung cancer
compared to patients with alternate diagnoses (24 of 28 v. 1
of 3, respectively, pZ 0.025). Among patients with primary
lung cancer, the ability to locate the PPL with the probe
was significantly associated with a positive diagnosis
(p Z 0.006).
A trend toward significance was seen for difference in
sensitivity for PPL 6 cm from the pulmonary hilum
compared to PPL >6 cm from the hilum (20 of 21 v. 5 of 8
respectively, p Z 0.058). Lesion size, lobar location, and
presence/absence of the CT-bronchus sign were not
observed to influence diagnostic performance of EBUS-TBLB
(data not shown).
Complications
There was a significant difference in the overall complica-
tion rate between the groups (EBUS 3% v. CT-PNB 27%,
p Z 0.03). Pneumothorax was noted in 1 subject in the
EBUS group. This was small and self-limiting. Significant
hemoptysis and pulmonary hemorrhage, as well as pain,
was noted in one subject in the CT-PNB group. This patient
required management in hospital and was discharged home
after 3 days. Biopsy in this patient was performed using
a 17-gauge coaxial needle, with pathologic examination
confirming nodular lymphoid hyperplasia. Both the large
needle size and the nature of the underlying lesion (CT-PNB
confirmed nodular lymphoid hyperplasia) may have
contributed to the risk of hemorrhage in this patient. Two
further patients undergoing CT-PNB experienced small self-
limiting pneumothoraces, and one patient experienced
a hydropneumothorax. All complications were managed
conservatively, with no patients requiring intercostal
catheter insertion.
All complications following CT-PNB were noted in
patients in whom the biopsy needle traversed aerated lung,
with biopsy of PPLs with pleural contact (nZ 5) associated
with no complications. Complications were seen in two of
four procedures performed by radiology registrars/fellows.
Comparison with rate of complications in procedures per-
formed by radiology consultants was non-significant
(p Z 0.24).
Discussion
This is the first randomized controlled trial to directly
compare CT-PNB and EBUS-TBLB for the investigation of
PPLs. Our results confirm that both procedures are able to
Table 1 Demographic and clinicoradiologic data for randomized patients.
EBUS-TBLB CT-PNB p-value
Subjects 32 19
Age (mean þ SD) 71 þ 11 67 þ 12 0.193
Gender (F/M) 16/16 7/12 0.36
Sizea (cm)
Mean 2.8 þ 1.4 4.1 þ 2.1 0.026
2 cm 12 4
>2 cm 20 12
Lobar positiona
RUL 9 6 NS
RML 2 0
RLL 5 5
LUL 10 2
LLL 6 3
Distancea (cm)
from pleura 3.2 þ 2.5 1.6 þ 1.7 0.017
from hilum 4.5 þ 2.5 4.9 þ 2.5 0.536
pleural contact 4 5 0.138
a of patients undergoing biopsy (n Z 16 for CT-PNB).
1708 D.P. Steinfort et al.accurately diagnose PPLs. The diagnostic accuracy of the
two modalities were comparable, with our results indi-
cating non-inferiority of EBUS-TBLB in comparison to CT-
PNB. Inherent in comparative effectiveness research is
comparison of both the benefits and harms between the
two procedures. Importantly, the complication rate
following CT-PNB was significantly higher than that
observed following EBUS-TBLB (27% v. 3%, p Z 0.03).
Diagnostic sensitivity for both procedures in our study is
consistent with previously published studies.2,23 A recentTable 2 Final diagnoses in all patients undergoing minimally in
Procedure
Diagnostic
EBUS (n Z 25) Adenocarcinoma
Squamous cell lung carcinoma
Small cell lung carcinoma
Large cell lung carcinoma
Non-small cell lung carcinoma
Mycobacterium tuberculosis
CT-PNB (n Z 13) Adenocarcinoma
Squamous cell lung carcinoma
Non-small cell lung carcinoma
Nodular lymphoid hyperplasia
Non-diagnostic
EBUS (n Z 7) Squamous cell lung carcinoma
Adenocarcinoma lung
Adenosquamous carcinoma lung
Chondroid hamartoma
Inflammatory mass
Metastatic breast carcinoma
CT-PNB (n Z 3) Inflammatory mass
Squamous cell carcinoma
EBUS e endobronchial ultrasound, CT-PNB e CT-guided percutaneous
a all lesions were observed to have resolved on subsequent CT chesmeta-analysis confirmed a point sensitivity for detection of
lung cancer of 0.73 for EBUS-TBLB in investigation of PPLs,
and sensitivity in studies where prevalence of malignancy
was greater than 75% was 0.83.23 No systematic review of
CT-PNB for investigation of PPLs has been published but
evidence-based clinical practice guidelines observe that
sensitivity for detection of malignancy using CT-PNB in most
studies exceeds 90%. However, approximately 20% of
procedures were non-diagnostic,2 reflecting the lower yield
of CT-PNB in benign conditions.vasive biopsy.
Method diagnosis established
14
3
3
2
2
1
7
4
1
1
2 VATS
1 CT-PNB
1 VATS
1 VATS
1 Radiologic surveillancea
1 VATS
2 Radiologic surveillancea
1 Bronchoscopy
needle biopsy, VATS e Video-assisted thoracoscopic surgery.
t.
Table 3 Diagnostic performance for detection of lung cancer, and complication rates for the two study groups.
EBUS-TBLB CT-PNB p-value
Diagnostic accuracy % (95%CI) 87.5% (71e96) 93.3% (68e99) 1.0
Sensitivitya % (95%CI) 86% (68e95) 92% (62e99) 1.0
Complications
Overall 1 (3%) 4 (27%) 0.03
pneumothorax 1 (3%) 3 (20%)
admission 0 (0%) 1 (7%)
ICC 0 0
deaths 0 0
a sensitivity for the detection of lung cancer.
EBUS v CT biopsy for PPL 1709Our findings suggest that neither modality is uniformly
preferable in the investigation of PPLs. If non-inferior in
diagnostic accuracy, EBUS-TBLB would be the preferred
procedure due to the lower complication rate. While non-
inferiority of EBUS-TBLB in evaluation of PPL is demon-
strated in our study, this applies only to clinicoradiologi-
cally similar PPLs. Clinical and radiologic features affecting
diagnostic and complication rates are well described for
both EBUS-TBLB and CT-PNB (Table 5). Individual random-
ized or cross-over trials examining the effect on diagnostic
accuracy of variation in each of these individual factors is
not feasible given the virtually infinite permutations of
these factors.
These results add to data from previous studies
regarding the effect of specific clinicoradiologic factors on
diagnostic sensitivity or complication rates. Such informa-
tion may be used to inform a clinical decision-making
algorithm to assist clinicians in selection of the most
appropriate test. The presence of features that predict
a lower diagnostic sensitivity for EBUS-TBLB may lead
clinicians to refer patients for evaluation with CT-PNB.
Alternatively, clinicoradiologic factors predicting a higher
rate of pneumothorax complicating CT-PNB may result in
selection of EBUS-TBLB as the primary investigation
modality. A significant number of eligible patients excluded
by referring physicians in our study were excluded on the
basis of such clinicoradiologic factors, suggesting that many
clinicians already make such assessments intuitively.
Cost-effectiveness models may also influence the
development of such a clinical algorithm. While diagnostic
accuracy appears equivalent, a lower complication rate
suggests that EBUS-TBLB may be the preferable test due to
a lower morbidity, and lower costs required to manage
these complications.Table 4 Comparison of radiologic features of PPLs between pa
versus those in whom EBUS was non-diagnostic. The only factor p
the lesion with the radial EBUS probe.
Diagnostic EBUS (n Z 24)
Lesion size (mean) 30.4
SD 14
Distance from pleura 3.5
SD 2.6
Distance from hilum 4.0
SD 2.6
Probe located within lesion 19Strengths and limitations
The study was designed as a randomized pragmatic trial in
order to replicate usual conditions in which clinical
decision-making regarding the choice of investigation for
a PPL occurs. We believe the prospective pragmatic study
design results in a high degree of external validity. We also
carefully defined patient eligibility in order to examine the
group of patients with PPL in whom we feel insufficient
evidence exists to inform clinical decision-making and in
whom the choice between EBUS-TBLB and CT-PNB is
frequently arbitrary. We deliberately excluded patients
with suspected lung cancer in whom we believe clinical
acumen was sufficient to guide initial investigation (eg.
patients with endobronchial disease, or suspected distant
metastases).
We recognize some limitations to our study. Diagnostic
accuracy and complication rates are reported to vary
widely for both procedures.2,23 The generalizability of our
results to other patient cohorts undergoing investigation for
PPL is contingent on individual proceduralists having similar
diagnostic sensitivity and complication rates to ours.
Significant deviation from our observed outcomes may alter
the decision regarding the most appropriate initial investi-
gation for PPLs.
While 14 patients eligible for randomization declined, or
were unable, to consent, reasons for failure to randomize
were unstated in a further 20 patients. The trial design
specified that clinicians may exclude patients from
randomization if clinical acumen suggested that one
procedure was preferred, and 28 patients were excluded on
this basis. We suspect that clinical acumen similarly
determined the optimal initial investigation in a significant
proportion of these 20 patients. Although selection biastients with lung cancer in whom EBUS-TBLB was diagnostic,
redictive for a diagnostic procedure was the ability to locate
Non-diagnostic EBUS (n Z 4) p-value
27 0.69
10
2.0 0.27
2.7
5.5 0.22
3.1
0 0.006
Table 5 Evidence-based summary of clinicoradiologic features affecting diagnostic yield & complication rates following
invasive biopsy of peripheral pulmonary lesions.
Radiologic
characteristic
Pleural
contact
Lesion size Lobar position Proximity to
pulmonary hilum
COPD Bronchus sign
<2 cm >5 cm Apico-posterior
left upper lobe
RML, RLL,
lingulaEffect on procedural
outcome:
Diagnostic accuracy
EBUS-TBLB Y31,32 Y 22 [37,38 Y/e37 [/e10,42 [31,32 e [/e43
CT-PNB e Y3336 e/Y33,3941 e e/Y41 e e e
Complication rates
EBUS-TBLB e e e e e e e e
CT-PNB YY31,44 [4547 e e [/e41,48 [4549 [[a,44,46,5052 e
RML e right middle lobe, RLL e right lower lobe, COPD e chronic obstructive pulmonary disease, EBUS-TBLB e endobronchial
ultrasound-guided transbronchial lung biopsy, CT-PNB e CT-guided percutaneous needle biopsy.
a as well as a higher complication rate, the rate of intercostal tube insertion in the event of a pneumothorax in patients with COPD is
also increased.44,47,48,53,54
1710 D.P. Steinfort et al.cannot be fully excluded, such a bias would be expected to
reduce the observed discrepancy in complication rates. Our
findings would therefore remain valid and significant.
We compared CT-PNB with bronchoscopy guided by radial
probe EBUS. Other bronchoscopic modalities not included in
our study designmaybe selectively utilized during diagnostic
bronchoscopy to further increase diagnostic accuracy.
Transbronchial needle aspiration (TBNA) guided by linear
probe EBUS may achieve diagnosis via sampling of central
parenchymal lesions,24,25 or mediastinal and hilar lymph
node metastases.24,26,27 EMN is an alternate guidance
mechanism however it is very expensive and diagnostic
accuracy is not significantly better than EBUS-TBLB.10 It may
be appropriate for selected patients though this remains
unclear. Consideration of the potential additional value of
these tools should be made when deciding between bron-
choscopic and percutaneous approaches to PPL biopsy.
The randomization process resulted in significant
differences between the two groups in lesion size (CT-PNB
4.1  2.1 cm v. EBUS-TBLB 2.8  1.4 cm, pZ 0.026) and in
the distance from pleura to the PPL (CT-PNB 1.6  1.7 v.
EBUS-TBLB 3.2  2.5, p Z 0.017). The discrepancy in both
factors would be expected to favor the CT-PNB arm of the
study, with smaller lesion size recognized as a factor in
lower diagnostic accuracy for both procedures, and shorter
distance between pleura and PPL predicting a lower rate of
pneumothorax complicating CT-PNB (see Table 5). We
believe therefore that this does not alter our finding of non-
inferiority.
The number of subjects is relatively small, though is
consistent with many published interventional bronchos-
copy studies. Sample size calculations were performed in
order to avoid a type II error (false negative finding) for the
primary outcome of complication rates. Given a statisti-
cally significant observed difference in complication rates,
our subject number, though small, is sufficient to address
the primary outcome of complication rates.Implications for future research
Randomized trials in the field of interventional pulmonol-
ogy are rare, and our results highlight the difficulty ofperforming such studies. The two major difficulties
encountered related to the unequal randomization of
subjects (both in terms of numbers per study arm as well as
clinical features), and the small proportion of patients
screened for trial inclusion that were successfully
randomized.
There is a significant chance when randomizing small
numbers of subjects that imbalances might be seen
between groups.28 Block (or restricted) randomization may
be used to ensure equal numbers of subjects per group, and
stratified randomization can be utilized to decrease the
odds of significant differences between groups. Response-
adaptive (Bayesian) randomization may also allow a reduc-
tion in required sample size without impairment of statis-
tical power.29
The pragmatic study design used resulted in exclusion of
a significant number of patients (Fig. 1), including those
with clinical stage N2/3 and clinical stage IV disease, as
well as those with poor performance status, as we felt the
clinical question did not apply to these patient groups. The
resultant small proportion of screened patients who were
randomized is therefore unsurprising, and is consistent with
the proportion of lung cancer patients with localized
disease at diagnosis.30 Future studies may be more effec-
tive if performed as multi-centre trials, and may also be
required to be more explanatory in design,14 to optimize
subject accrual. Alternatively, further studies examining
clinicoradiologic features influencing diagnostic sensitivity
and complication rates of EBUS-TBLB and CT-PNB may be
more valuable in informing clinical decision-making algo-
rithms. Prospective validation of any such algorithm would
be required prior to their adoption in routine clinical
practice.Conclusion
Both modalities examined have very good diagnostic accu-
racy in the investigation of peripheral pulmonary lesions.
Our findings suggest that diagnostic accuracy of EBUS-TBLB
in evaluation of PPL is non-inferior to CT-PNB. However,
clinicoradiologic factors influencing diagnostic accuracy
and complication rates should allow clinicians to determine
EBUS v CT biopsy for PPL 1711which procedure is most appropriate as the initial investi-
gation for individual patients. Complication rates following
EBUS-TBLB are significantly lower than following CT-PNB
and as a result, if expected diagnostic sensitivity is equiv-
alent, patients should be preferentially referred for EBUS-
TBLB for investigation of PPL. Further studies are required
to allow clinicians to accurately assess expected diagnostic
accuracy, and complication rates, for individual patients on
the basis of clinicoradiologic features.
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